#United States #San Diego #Healthcare Innovations #Neurocrine Biosciences #Jefferies Conference

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Neurocrine Biosciences, a prominent player in the biopharmaceutical industry, has announced that its executives are all set to represent the company at the 2026 Jefferies Global Healthcare Conference. This event will take place in London on November 17, 2026, at 3:30 PM Greenwich Mean Time (10:30 AM Eastern Time). This conference is a pivotal gathering for investors, healthcare professionals, and industry experts to discuss impactful innovations and advancements in the healthcare sector.

Event Details

The conference offers a platform for Neurocrine executives to delve into the company’s diverse portfolio and ongoing projects. Attendees can expect to learn about groundbreaking treatments developed to address significant unmet medical needs, particularly in the domain of neuroscience, psychiatry, and other specialized areas. A webcast of the event will be accessible on Neurocrine Biosciences’ official website, providing an opportunity for those unable to attend the conference to follow along. Additionally, a replay of the presentation will be available about an hour after its conclusion and will be archived for a month for easy access.

About Neurocrine Biosciences

Founded with a vision to alleviate suffering through innovative science, Neurocrine Biosciences has dedicated over three decades to researching and developing life-changing treatments for patients grappling with complex neurological, psychiatric, endocrine, and immunological disorders. The company stands out in its commitment to understanding the intricate connections between the brain and body systems, guiding its approach to creating novel therapies that substantially improve patients' quality of life.

Neurocrine's current product lineup includes FDA-approved therapies for conditions such as tardive dyskinesia, chorea related to Huntington’s disease, congenital adrenal hyperplasia, and hyperphagia in patients with Prader-Willi syndrome. Furthermore, the company boasts a robust pipeline consisting of multiple compounds undergoing mid- to late-phase clinical trials across its primary therapeutic areas.

Corporate Commitment to Healthcare

Neurocrine Biosciences operates with the mission of developing accessible and effective treatments that address significant health challenges. With a focus on conditions that traditional medicine often overlooks, Neurocrine strives to pioneer innovative solutions that enhance the lives of countless individuals. The upcoming presentation at the Jefferies Global Healthcare Conference highlights the company's ongoing dedication to healthcare advancement and its proactive role within the biopharmaceutical landscape.

For more information about Neurocrine Biosciences and its latest breakthroughs, visit their social media channels on LinkedIn, X, Facebook, and YouTube. Through these platforms, the organization shares regular updates and engages with the community on matters concerning health and innovation.

Neurocrine Biosciences emphasizes that “You Deserve Brave Science,” encapsulating its commitment to bold and transformative scientific research. As the company prepares for the 2026 Jefferies Global Healthcare Conference, it looks forward to sharing its journey and vision for the future of healthcare.

In conclusion, Neurocrine's participation in this high-profile conference is a testament to its influence in the field of healthcare and its promise to continue pioneering drug development initiatives that provide hope and relief to patients worldwide.